Browse by Medical Category
Accepting New Patients
Dr Papakostas is Associate Professor of Psychiatry at Harvard Medical School and Director for Treatment-Resistant Depression Studies at the Massachusetts General Hospital Department of Psychiatry.
Go To Programs
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
George I. Papakostas is Associate Professor of Psychiatry at Harvard Medical School and Director of Treatment-Resistant Depression Studies in the Department of Psychiatry at Massachusetts General Hospital in Boston, Massachusetts. He is also field editor for Psychopharmacology for the World Journal of Biological Psychiatry and on the editorial board of the journal Psychiatry Research. The focus of Dr Papakostas research includes the pharmacotherapy of major depressive disorder (MDD) including treatment-resistant depression, the study of the placebo effect and its relevance to clinical trial design in MDD, and the study of clinical and biologic markers of treatment outcome in MDD. Dr Papakostas has received numerous national and international research awards from sources including the American College of Neuropsychopharmacology and the American Psychiatric Association. He is author or co-author of over 150 clinical and scientific publications and book chapters, and is author of the book entitled: Pharmacotherapy for Depression (World Scientific Publishing and Imperial College Press). Dr. Papakostas is often invited throughout the United States and abroad to lecture on a wide range topics pertaining to the treatment of depression. To date, he has delivered more than 100 lectures at National or International meetings in more than 30 countries.
Dr. Papakostas is involved in overseeing numerous studies focusing on the diagnosis, treatment, and management of Major Depressive Disorder that is resistant or refractory to standard therapy. He is also active in educating clinicians locally, regionally, nationally, and internationally on the management of major depressive disorder, as well as in disseminating cutting-edge research in this field of study through numerous manuscripts published in top-notch scientific journals. Dr. Papakostas is also co0author of the book entitled: "Parmacotherapy for Depression and Treatment-Resistant Depression" which, currently is the most up-to-date and comprehensive source document focusing on the treatment of this medical illness.
Papakostas GI, Fava M. Pharmacotherapy for Depression and Treatment-Resistant Depression. 1st Edition. Singapore: World Scientific Publishing; 2010.
Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors (SRIs) for SRI- non-responders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry. (In press).
Nelson JC, Papakostas GI. Augmentation of Antidepressants with Atypical Antipsychotic Agents for Treatment-Resistant Depression: An updated meta-analysis. Am J Psychiatry. 2009; 166(9): 980-991.
The initial assessment of a blood test to help diagnose major depressive disorder indicates it may become a useful clinical tool. A team including MGH researchers reports that analyzing levels of nine biomarkers accurately distinguished patients diagnosed with depression from control participants without significant false-positive results.
Back to Top